公开(公告)号：USRE45907E1

公开(公告)日：2016-03-01

申请号：US14180238

申请日：2014-02-13

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Charles Manly Garner, III ,  Robert Ronald Kane ,  Kevin G. Pinney ,  Joseph Anthony Prezioso ,  Klaus Edvardsen

IPC分类号： A01N57/00 ,  C07C43/23 ,  C07C45/63 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07F9/12 ,  C07C237/04 ,  C07C47/575

CPC分类号： C07C43/23 ,  C07C45/63 ,  C07C47/575 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07C237/04 ,  C07F9/12

摘要： Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

公开(公告)号：USRE45720E1

公开(公告)日：2015-10-06

申请号：US14180209

申请日：2014-02-13

申请人： OXiGENE, Inc. ,  Baylor University

发明人： David J. Chaplin ,  Charles Manly Garner, III ,  Robert Ronald Kane ,  Kevin G. Pinney ,  Joseph Anthony Prezioso ,  Klaus Edvardsen

IPC分类号： C07C207/00 ,  C07C207/04 ,  C07C205/37 ,  C07C205/00 ,  C07C217/00 ,  C07C237/00 ,  C07C217/84 ,  C07C237/04 ,  C07C43/00 ,  C07C45/63 ,  C07C43/23 ,  C07F9/00 ,  C07C9/12 ,  C07C47/575 ,  C07F9/12

CPC分类号： C07C43/23 ,  C07C45/63 ,  C07C47/575 ,  C07C205/37 ,  C07C207/04 ,  C07C217/84 ,  C07C237/04 ,  C07F9/12

摘要： Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.